Sera from calves infected in utero or postnatally with bovine rotavirus NCDV or postnatally with human rotavirus D (serotype 1) were tested by plaque reduction neutralization assay for antibody to bovine rotavirus and to three serotypes of human rotavirus. Homologous antibody developed in all animals, but antibody to heterologous rotaviruses developed mainly in animals exposed in utero to bovine rotavirus. The development of heterologous antibody may explain the immunological implications for cross-protection, previously observed between bovine and human rotavirus in experimentally infected calves.
Gnotobiotic calves which had been inoculated with bovine rotavirus in utero have previously been studied postnatally for homologous and heterologous rotavirus immunity (21) . Wild-type bovine rotavirus (NCDV) administered to calves in utero 2 to 14 weeks before delivery induced both homologous protection against postnatal NCDV challenge and heterologous protection against postnatal challenge with human rotavirus serotype 1, represented by strain D (HRV-D). Subsequent to that study, it was shown that NCDV and HRV-D are distinct serotypes by neutralization (18, 20) , and it thus became difficult to explain the immunity that had been observed. When a plaque reduction neutralization assay for measuring neutralizing antibody to human rotavirus became available, the sera from this study were examined for antibody to both bovine rotavirus and three human rotavirus serotypes (19) . At this time, four to five serotypes of human rotavirus have been described (11, 13, 15, 18, 19) , and the numbering system initiated by Thouless et al. has been used here (13 Plaque reduction neutralization assay. Plaque reduction neutralization assay was performed in MA104 cell monolayers as previously described (18) to measure neutralizing antibody to the four serotypically distinct rotaviruses described below (4, 20) . Bovine rotavirus UK was isolated originally in England (2) and is similar if not identical to the NCDV strain by neutralization assay (20; R. G. Wyatt et al., unpublished data). Human rotavirus Wa, isolated directly in cell culture after serial passage in gnotobiotic piglets, is almost identical to HRV-D by neutralization assay (18) (19) (20) and represents human rotavirus serotype 1 (19) . Human rotavirus DS-1 is a reassortant rotavirus that was prepared by genetic reassortment with a bovine rotavirus UK temperature-sensitive mutant and has the neutralization phenotype of the DS-1 parent (4); this reassortant was used previously to characterize DS-1 serotype (18), subsequently designated human rotavirus serotype 2 (19) . Rhesus monkey rotavirus MMU18006 (supplied by N. J. Schmidt) is almost identical to members of human rotavirus serotype 3 (12, 18) . A 60% reduction in mean plaque count for each virus was used to determine antibody titer (18) . Cross-reactive serum antibody was considered significant if there was less than a 20-fold difference between homologous and heterologous titers (18) .
Enzyme immunoassay for rotavirus detection and subgrouping. Enzyme immunoassay, as previously described, was used to measure rotavirus antigens by the use of preimmune and hyperimmune rotavirus antiserum as capture antibody in an alternate row fashion (8) . Subgrouping of rotaviruses in the form of calf fecal suspensions was performed by enzyme immunoassay with the use of monoclonal antibodies as recently described (5, 19 (Table 1) . Homologous and heterologous antibody levels tended to increase with longer times of exposure to antigen (Table 1) . Postinfection antisera from animals exposed postnatally to NCDV for the first time contained low or undetectable levels of heterotypic antibody to human rotavirus serotypes (Table 1) ; none of these four animals developed significant levels of heterotypic serum antibody to at least two of the human rotavirus serotypes, a finding in contrast to that found in the group exposed to NCDV in utero (P < 0.05, Fisher exact test). In only one case, in which HRV-D was administered postnatally ( utero. This unnatural route of immunization and prolonged exposure of the fetus to viral antigens may explain these high levels of heterotypic antibody. Nevertheless, rotavirus infection in utero not only rendered the calves resistant to disease on subsequent challenge with HRV-D, but also significantly reduced fecal shedding of rotavirus. The development of such heterotypic antibody after exposure to bovine rotavirus and the alteration of rotaviral shedding on subsequent challenge with heterologous human rotavirus may explain the immunity previously observed and described (21) . It may also provide a further rationale for the use of a bovine rotavirus or other animal rotavirus as a vaccine in humans.
The use of heterologous bovine rotavirus to protect piglets against disease caused by porcine rotavirus has been attempted. In one study, however, it could not be demonstrated that the attenuated live bovine rotavirus strain (Scourvax-Reo; Norden Laboratories, Lincoln, Nebr.) infected the piglets, and immunity did not result (10) . In another study, a limited degree of protection was observed: three of six piglets which developed high levels of immunofluorescent antibody after exposure to the same live bovine rotavirus vaccine were protected against disease and virus excretion on challenge with porcine rotavirus (16) . In a similar fashion, live attenuated bovine rotavirus, strain RIT 4237, has been evaluated in piglets for its ability to confer heterologous protection against infection caused by human rotaviruses. Piglets inoculated with bovine rotavirus, followed by human rotavirus 7, 10, or 14 days later, shed significantly less virus after the latter challenge than did controls (1Sa; M. Lobmann, P. Charlier, A. Homologous and heterologous immunity in gnotobiotic piglets has also been evaluated between selected porcine, bovine, simian, and canine rotaviruses. Virulent porcine or avirulent simian rotaviruses were used for challenge, and in these instances, immunity appeared to be serotype specific as measured by disease and virus excretion (3) . In another study in gnotobiotic calves, foal or human rotavirus was administered to three animals, with each administration followed by bovine rotavirus as challenge inoculum. In both cases, one of the three animals was protected against diarrhea and virus excretion (17) . Finally, five human rotavirus strains were administered to gnotobiotic piglets, and three of these strains infected the animals. When the piglets were challenged 2 weeks later with porcine rotavirus, animals which had been infected with human rotavirus were protected against diarrhea, whereas animals which had not been infected with human rotavirus were not protected (14) . The shedding of rotavirus after porcine rotavirus challenge was documented but not quantitated by electron microscopy; thus, its effect on virus shedding could not be assessed.
Identification and characterization of rotavirus gene products which induce neutralizing antibody should contribute to a better understanding of in vitro and in vivo neutralization. Currently, neutralization function has been associated with the products of at least four genes: nos. 4, 6, 8 or 9, and 10 (1, 6, 7, 9) . It 
